OncoZenge
OncoZenge AB is a Swedish clinical-stage pharmaceutical company focused on developing BupiZenge™, a locally acting nonopioid tablet for oral pain relief. The company’s work centers on product development, clinical validation, and partnering for commercialization across Europe and selected international markets.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueDevelopment of the BupiZenge™ tablet formulation for oral mucositis and related pain indications.
Phase III registrational study work, including trial design, site management, and regulatory support.
Out-licensing and commercialization agreements for Europe, GCC, and other markets.
Exploration of additional indications such as dental and other oral pain applications.
Customers
OncoZenge’s direct counterparties are pharmaceutical partners, distributors, and commercialization licensees rather than end patients. The eventual users are patients suffering from oral mucositis and other oral pain conditions, while the buyers and commercial partners are regional pharma companies that fund, register, manufacture, or distribute the product.
Buy rights to commercialize BupiZenge™ in defined territories and help fund market entry.
Support trial execution, regulatory filings, and development operations needed for approval.
End users of the product for pain relief during cancer treatment-related oral mucositis.
Prescribers and treatment centers that adopt the product if approved for oral pain management.
Potential buyers for expanded uses such as dental care, endoscopy, and tonsillectomy.
Strategy
OncoZenge’s strategy is to complete the European Phase III program and use that data to support commercialization and regulatory expansion. The company also seeks regional partners to accelerate market access in territories where the European approval package can be leveraged, while exploring additional indications beyond oral mucositis.
Clinical success is the key gate to approval and future commercialization.
Licensing reduces the need to build a full commercial organization in every market.
Additional indications can broaden the addressable market and extend product life.
These markets require tailored regulatory and partnership approaches.
Geography
OncoZenge is headquartered in Stockholm, Sweden and operates as a Swedish listed development company. Its commercialization strategy is built around Europe first, with additional partnering ambitions in the GCC region, China, the United States, Latin America, parts of Asia, Canada, and Africa.
Risks
OncoZenge is exposed to clinical, regulatory, financing, and partnership execution risk because its value depends on a single lead asset moving through development and approval. As a clinical-stage company with limited operating cash generation, it also faces funding risk, while patent protection, competition, and geopolitical conditions can affect both development and capital access.
- Phase III clinical development riskImpact: CriticalLikelihood: Medium
The company’s lead asset must succeed in registrational testing before broad commercialization.
Exposure: BupiZenge™ European Phase III trial
- Financing and liquidity riskImpact: HighLikelihood: Medium
The company does not yet generate sufficient revenue to fund operations internally.
Exposure: Ongoing development and regulatory work
- Partner dependency riskImpact: HighLikelihood: Medium
Commercialization relies on third-party pharma partners in key regions.
Exposure - Geopolitical and capital market riskImpact: MediumLikelihood: Medium
Market volatility can make fundraising and cross-border execution harder.
Exposure - Patent and intellectual property riskImpact: MediumLikelihood: Low
Value creation depends on protecting formulations and market exclusivity.
Exposure: BupiZenge™ formulations and related patents
Accounting
Judgemental itemsClinical-stage projects are currently expensed, which affects reported operating loss and asset values.
Impact: Development spending flows through the income statement rather than being deferred.
Patents are activated and must be assessed for recoverability if project prospects change.
Impact: Could affect balance-sheet asset values and impairment charges.
Loss carryforwards may be restricted or lost after ownership changes.
Impact: Affects future tax shields and deferred tax asset recognition.
Directed share issues and convertible instruments affect equity and financing presentation.
Impact: Impacts share capital, share premium, and dilution analysis.
Similar listed companies
Publicly listed companies with a comparable business focus.
Oncopeptides
ONCO · Health Care
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases.
Cinclus Pharma Holding
CINPHA · Health Care
Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD).
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
OKYO Pharma Ltd
OKYO · Biological Products, (No Diagnostic Substances)
OKYO Pharma Ltd is a U.S.-listed clinical-stage biopharmaceutical company focused on developing investigational therapies for neuropathic corneal pain and other anterior segment eye diseases.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Last updated: 24/09/2026